Lonza Signs Applied Protein Services Agreement with ImmuneMed for Immunogenicity Risk Assessment and Deimmunization of Novel Protein

13-Dec-2011 - Switzerland

Lonza announced an agreement with  ImmuneMed, Inc. for the in silico screening followed by deimmunization of their Virus Suppressing Factor (VSF), under investigation for the treatment of viruses such as the encephalomyocarditus, influenza and hepatitis. Under the agreement, Lonza will perform an immunogenicity risk assessment using their latest version (v.3) of their T-cell epitope prediction engine, Epibase™. This assessment will help reduce ImmuneMed’s attrition rate in their drug development program. The pre-clinical assessment will be performed at Lonza’s protein services and development facility in Cambridge, UK.
 
“We are excited to support Korea’s growing biotechnology landscape with our risk assessment services,” said Janet White, Head of Lonza’s Development Services. “This partnership is a direct reflection of Lonza’s commitment to the success of our customers’ pre-clinical pipeline.”

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance